BIS issued an Interim Final Rule that amends the Export Administration Regulation (EAR) to address dual use export ...
Barchart on MSN35m
This Penny Stock Just Doubled on Clinical Trial Results. Analysts Think It Can Surge 266% From Here.Biotechnology is a high-risk, high-reward landscape where innovation determines success. Yet, occasionally, a small player ...
Investor's Business Daily on MSN26m
Neurocrine Crumbles On Lackluster Guidance For Its Bread-And-Butter DrugNeurocrine stock took a hit late Thursday after the biotech company issued a light 2025 outlook for its drug, Ingrezza.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback